Peer-reviewed veterinary case report
Differences in anemia and outcomes in dogs with two platelet disorders
By Cooper, S A et al.·Published in The Journal of small animal practice·2016·Department of Veterinary Clinical Sciences, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Clinical data, clinicopathologic findings and outcome in dogs with amegakaryocytic thrombocytopenia and primary immune-mediated thrombocytopenia.
- Species:
- dog
Plain-English summary
A group of dogs with low platelet counts were diagnosed with either amegakaryocytic thrombocytopenia or primary immune-mediated thrombocytopenia. The dogs with amegakaryocytic thrombocytopenia showed more severe symptoms, including anemia and multiple signs of bleeding, and most of them required blood transfusions. Unfortunately, six out of seven dogs with amegakaryocytic thrombocytopenia did not survive their treatment, while the prognosis was better for those with primary immune-mediated thrombocytopenia, with only five out of thirty-four not surviving. This highlights the seriousness of amegakaryocytic thrombocytopenia in dogs.
People also search for: dog low platelet count symptoms · dog bleeding problems treatment · amegakaryocytic thrombocytopenia prognosis
Abstract
OBJECTIVES: The aim of this study was to identify distinguishing characteristics between dogs diagnosed with amegakaryocytic thrombocytopenia and those diagnosed with presumed primary peripheral immune-mediated thrombocytopenia. Presenting clinical and clinicopathologic data and outcomes were compared between the two groups. METHODS: Retrospective study performed on seven client-owned dogs diagnosed with amegakaryocytic thrombocytopenia and 34 client-owned dogs with primary peripheral immune-mediated thrombocytopenia. RESULTS: All dogs in the amegakaryocytic thrombocytopenia group were anaemic on presentation with a median haematocrit of 23% (range 9·4 to 36), while the primary peripheral immune-mediated thrombocytopoenia group had a median presenting haematocrit of 35% (range 10 to 53). Dogs with amegakaryocytic thrombocytopenia had a median of five (range 4 to 7) clinical signs of bleeding compared to a median of three (range 0 to 6) in the primary peripheral immune-mediated thrombocytopenia group with 86% (6 of 7) of amegakaryocytic thrombocytopenia dogs requiring a blood transfusion compared to 41% (14 of 34) of primary peripheral immune-mediated thrombocytopenia dogs. Six of the seven amegakaryocytic thrombocytopenia dogs did not survive to discharge, while only five of the 34 primary peripheral immune-mediated thrombocytopenia dogs did not survive to discharge. CLINICAL SIGNIFICANCE: The clinical presentation of dogs with amegakaryocytic thrombocytopenia and primary peripheral immune-mediated thrombocytopenia is similar, but dogs with amegakaryocytic thrombocytopenia had a more severe clinical course compared to primary peripheral immune-mediated thrombocytopenia dogs. The prognosis for dogs with amegakaryocytic thrombocytopenia is poor.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/26799165/